BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 10980115)

  • 1. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas.
    Iacobuzio-Donahue CA; Klimstra DS; Adsay NV; Wilentz RE; Argani P; Sohn TA; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Am J Pathol; 2000 Sep; 157(3):755-61. PubMed ID: 10980115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression.
    Iacobuzio-Donahue CA; Wilentz RE; Argani P; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Am J Surg Pathol; 2000 Nov; 24(11):1544-8. PubMed ID: 11075857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas.
    Sasaki S; Yamamoto H; Kaneto H; Ozeki I; Adachi Y; Takagi H; Matsumoto T; Itoh H; Nagakawa T; Miyakawa H; Muraoka S; Fujinaga A; Suga T; Satoh M; Itoh F; Endo T; Imai K
    Oncol Rep; 2003; 10(1):21-5. PubMed ID: 12469138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma.
    Biankin AV; Biankin SA; Kench JG; Morey AL; Lee CS; Head DR; Eckstein RP; Hugh TB; Henshall SM; Sutherland RL
    Gut; 2002 Jun; 50(6):861-8. PubMed ID: 12010891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma.
    Lüttges J; Zamboni G; Longnecker D; Klöppel G
    Am J Surg Pathol; 2001 Jul; 25(7):942-8. PubMed ID: 11420467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.
    Wilentz RE; Su GH; Dai JL; Sparks AB; Argani P; Sohn TA; Yeo CJ; Kern SE; Hruban RH
    Am J Pathol; 2000 Jan; 156(1):37-43. PubMed ID: 10623651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas.
    Basturk O; Chung SM; Hruban RH; Adsay NV; Askan G; Iacobuzio-Donahue C; Balci S; Zee SY; Memis B; Shia J; Klimstra DS
    Virchows Arch; 2016 Nov; 469(5):523-532. PubMed ID: 27591765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
    Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
    Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling.
    McCarthy DM; Brat DJ; Wilentz RE; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Hum Pathol; 2001 Jun; 32(6):638-42. PubMed ID: 11431719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologically different subgroups of invasive ductal carcinoma of the pancreas: Dpc4 status according to the ratio of intraductal carcinoma components.
    Takahashi H; Oda T; Hasebe T; Aoyagi Y; Kinoshita T; Konishi M; Nakagohri T; Inoue K; Takahashi S; Kawahira H; Monden M; Ochiai A
    Clin Cancer Res; 2004 Jun; 10(11):3772-9. PubMed ID: 15173084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas.
    Adsay NV; Merati K; Basturk O; Iacobuzio-Donahue C; Levi E; Cheng JD; Sarkar FH; Hruban RH; Klimstra DS
    Am J Surg Pathol; 2004 Jul; 28(7):839-48. PubMed ID: 15223952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
    Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
    Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas.
    Oda Y; Aishima S; Morimatsu K; Hayashi A; Shindo K; Fujino M; Mizuuchi Y; Hattori M; Tanaka M; Oda Y
    Hum Pathol; 2013 Aug; 44(8):1487-98. PubMed ID: 23465281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.
    Wilentz RE; Iacobuzio-Donahue CA; Argani P; McCarthy DM; Parsons JL; Yeo CJ; Kern SE; Hruban RH
    Cancer Res; 2000 Apr; 60(7):2002-6. PubMed ID: 10766191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.
    Sato N; Ueki T; Fukushima N; Iacobuzio-Donahue CA; Yeo CJ; Cameron JL; Hruban RH; Goggins M
    Gastroenterology; 2002 Jul; 123(1):365-72. PubMed ID: 12105864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity.
    Sohn TA; Yeo CJ; Cameron JL; Iacobuzio-Donahue CA; Hruban RH; Lillemoe KD
    Ann Surg; 2001 Sep; 234(3):313-21; discussion 321-2. PubMed ID: 11524584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients.
    Adsay NV; Conlon KC; Zee SY; Brennan MF; Klimstra DS
    Cancer; 2002 Jan; 94(1):62-77. PubMed ID: 11815961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas.
    Miyasaka Y; Nagai E; Yamaguchi H; Fujii K; Inoue T; Ohuchida K; Yamada T; Mizumoto K; Tanaka M; Tsuneyoshi M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4371-7. PubMed ID: 17671118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
    Furukawa T; Fujisaki R; Yoshida Y; Kanai N; Sunamura M; Abe T; Takeda K; Matsuno S; Horii A
    Mod Pathol; 2005 Aug; 18(8):1034-42. PubMed ID: 15832194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis.
    Adsay NV; Merati K; Andea A; Sarkar F; Hruban RH; Wilentz RE; Goggins M; Iocobuzio-Donahue C; Longnecker DS; Klimstra DS
    Mod Pathol; 2002 Oct; 15(10):1087-95. PubMed ID: 12379756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.